Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNKSR1 | Q969H4 | 1/20 | 0.45 |
| ▸ | DPP4 | P27487 | 2/20 | 0.43 |
| ▸ | TTR | P02766 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | FDPS | P14324 | 1/20 | 0.39 |
| ▸ | MLYCD | O95822 | 1/20 | 0.38 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28880197 | 1.00 | CNKSR1 (0.45) | CNKSR1DPP4TTRCA12CA1 | |
| SCHEMBL26141728 | 1.00 | CNKSR1 (0.45) | CNKSR1DPP4TTRCA12CA1 | |
| SCHEMBL10313842 | 0.81 | ALDH1A1 (0.45) | CNKSR1DPP4TTRCA12CA1 | |
| SCHEMBL10314030 | 0.81 | ALDH1A1 (0.45) | CNKSR1DPP4TTRCA12CA1 | |
| SCHEMBL29363760 | 0.79 | CA12 (0.46) | CNKSR1DPP4TTRCA12CA1 | |
| SCHEMBL29005494 | 0.79 | CA12 (0.46) | CNKSR1DPP4TTRCA12CA1 | |
| SCHEMBL23705991 | 0.79 | TDP1 (0.42) | CNKSR1DPP4TTRCA12CA1 | |
| SCHEMBL31153405 | 0.78 | CNKSR1 (0.40) | CNKSR1DPP4TTRCA12CA1 | |
| SCHEMBL29363532 | 0.78 | DPP4 (0.42) | CNKSR1DPP4TTRCA12CA1 | |
| SCHEMBL29005510 | 0.78 | DPP4 (0.42) | CNKSR1DPP4TTRCA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12441726-B2 | Compounds and uses thereof | FOGHORN THERAPEUTICS, INC. (US) | 2025-10-14 | — | — | US | disclosed |
| EP-4547336-A1 | USP1 INHIBITORS AND USES THEREOF | Zentaur Therapeutics USA Inc. (US) | 2025-05-07 | — | — | EP | disclosed |
| US-20240092779-A1 | USP1 INHIBITORS AND USES THEREOF | ZENTAUR THERAPEUTICS USA INC. | 2024-03-21 | — | — | US | disclosed |
| WO-2024006879-A1 | USP1 INHIBITORS AND USES THEREOF | ZENTAUR THERAPEUTICS USA INC. (US) | 2024-01-04 | — | — | WO | disclosed |
| US-20230145003-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-05-11 | — | — | US | disclosed |
| EP-4096667-A1 | COMPOUNDS AND USES THEREOF | Foghorn Therapeutics Inc. (US) | 2022-12-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240092779-A1 | USP1 INHIBITORS AND USES THEREOF | USP1, USP28, USP2 | CNKSR1 2774/4885DPP4 234/4885TTR 2155/4885 |
| US-12441726-B2 | Compounds and uses thereof | VHL, CLN6, TFEB | CNKSR1 2102/4885DPP4 4159/4885TTR 3059/4885 |
| US-20230145003-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, TFEB | CNKSR1 2102/4885DPP4 4159/4885TTR 3059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.